Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federica Fazzini

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Nature Communications|March 22, 2020
OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidationBernd Schöpf, Hansi Weissensteiner, Georg Schäfer, et al.
Scientific Reports|January 24, 2024
Nuclear and mitochondrial genetic variants associated with mitochondrial DNA copy numberAdriana Koller, Michele Filosi, Hansi Weissensteiner, et al.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2023
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trialDavide Melisi, Camilla Zecchetto, Valeria Merz, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Nature Communications|March 22, 2020
OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidationBernd Schöpf, Hansi Weissensteiner, Georg Schäfer, et al.
Scientific Reports|January 24, 2024
Nuclear and mitochondrial genetic variants associated with mitochondrial DNA copy numberAdriana Koller, Michele Filosi, Hansi Weissensteiner, et al.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2023
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trialDavide Melisi, Camilla Zecchetto, Valeria Merz, et al.
Pageof 2